Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

被引：0

作者：

Eyre, Toby ^{[1
]}

Pagel, John M. ^{[2
]}

Coombs, Catherine C. ^{[3
]}

Shah, Nirav N. ^{[4
]}

Lamanna, Nicole ^{[5
]}

Lech-Maranda, Ewa ^{[6
]}

Woyach, Jennifer ^{[7
]}

Wierda, William G. ^{[8
]}

Cheah, Chan Y. ^{[9
,10
]}

Roeker, Lindsey ^{[11
]}

Patel, Manish R. ^{[12
]}

Fakhri, Bita ^{[13
]}

Barve, Minal A. ^{[14
]}

Tam, Constantine S. ^{[15
,16
]}

Lewis, David ^{[17
]}

Gerson, James N. ^{[18
]}

Alencar, Alvaro ^{[19
]}

Taylor, Justin ^{[19
]}

Abedel-Wahab, Omar ^{[11
]}

Ghia, Paolo ^{[20
,21
]}

Schuster, Stephen J. ^{[18
]}

Chen, Jessica ^{[22
]}

Nair, Binoj ^{[23
]}

Tsai, Donald E. ^{[23
]}

Ku, Nora C. ^{[23
]}

Davids, Matthew S. ^{[24
,25
]}

Brown, Jennifer R. ^{[24
,25
]}

Jurczak, Wojciech ^{[26
]}

Mato, Anthony R. ^{[11
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[2] Swedish Canc Inst, Seattle, WA USA

[3] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[4] Med Coll Wisconsin, Brookfield, WI USA

[5] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[6] Inst Hematol & Transfus Med, Krakow, Poland

[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Linear Clin Res, Perth, WA, Australia

[10] Sir Charles Gairdner Hosp, Perth, WA, Australia

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[13] Univ Calif San Francisco, San Francisco, CA 94143 USA

[14] Mary Crowley Canc Res, Dallas, TX USA

[15] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[16] Univ Melbourne, Melbourne, Vic, Australia

[17] Derriford Hosp, Plymouth Hosp NHS Trust, Plymouth, Devon, England

[18] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[19] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[20] Univ Vita Salute San Raffaele, Milan, Italy

[21] IRCCS Osped San Raffaele, Milan, Italy

[22] Eli Lilly & Co, Indianapolis, IN 46285 USA

[23] Loxo Oncol Lilly, Stamford, CT USA

[24] Dana Farber Canc Inst, Boston, MA 02115 USA

[25] Harvard Med Sch, Boston, MA 02115 USA

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：37 / 38

页数：2

共 50 条

[41] BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
Mato, Anthony R.
Wierda, William G.
Pagel, John M.
Davids, Matthew S.
Zinzani, Pier Luigi
Lu, Yi
Liu, Hui
Shahda, Safi
Leow, Ching Ching
Tam, Constantine S.
Woyach, Jennifer A.
Eyre, Toby A.
BLOOD, 2021, 138 : 3742 - +
[42] Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)
Lin, Kevin H.
Huynh, Lynn
Yang, Xiaoqin
Zanardo, Enrico
Matay, Lisa
Pinaire, Megan
Liborski, Daria
McDonough, Mikaela M.
Foreman, Jillian
Farooqui, Mohammed Z. H.
De Nigris, Enrico
Gandra, Shravanthi R.
Sarpong, Eric M.
Duh, Mei Sheng
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2023, 142
[43] The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies
Burger, Jan A.
O'Brien, Susan
Fowler, Nathan
Advani, Ranjana
Sharman, Jeff Porte
Furman, Richard R.
Izumi, Raquel
Buggy, Joseph
Loury, David
Hamdy, Ahmed
Byrd, John C.
Blum, Kristie A.
BLOOD, 2010, 116 (21) : 32 - 32
[44] Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
Brown, Jennifer R.
Sharman, Jeff Porter
Harb, Wael A.
Kelly, Kevin R.
Schreeder, Marshall T.
Sweetenham, John W.
Barr, Paul M.
Foran, James M.
Gabrilove, Janice Lynn
Kipps, Thomas J.
Ma, Shuo
O'Brien, Susan Mary
Evans, Erica
Lounsbury, Heather
Silver, Bruce A.
Singh, Juswinder
Stiede, Kathryn
Westlin, William
Witowski, Steven
Mahadevan, Daruka
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[45] PHASE 1B TRIAL OF AVL-292, A COVALENT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-NON-HODGKIN LYMPHOMA (B-NHL)
Mahadevan, D.
Brown, J.
Harb, W.
Kelly, K.
Schreeder, M.
Sweetenham, J.
Barr, P.
Foran, J.
Gabrilove, J.
Kipps, T.
Ma
O'Brien, S. O.
Evans, E.
Lounsbury, H.
Silver, B.
Singh, J.
Stiede, K.
Westlin, W.
Witowski, S.
Sharman, J.
HAEMATOLOGICA, 2012, 97 : 58 - 59
[46] COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)-A two-cohort phase II study.
Wendtner, Clemens-Martin
Byrd, John C.
Foa, Robin
Greil, Richard
Hillmen, Peter
Jager, Ulrich
Jurczak, Wojciech
Kelemen, Peter
Laribi, Kamel
Munir, Talha
Schetelig, Johannes
Staber, Philipp B.
Stilgenbauer, Stephan
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[47] BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
Wierda, William G.
Pagel, John M.
Davids, Mathew S.
Zinzani, Pier Luigi
Lu, Yi
Liu, Hui
Shahda, Safi
Leow, Ching Ching
Tam, Constantine S.
Woyach, Jennifer
Eyre, Toby A.
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S267
[48] Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial
Cull, Gavin
Simpson, David
Opat, Stephen
Burger, Jan A.
Trotman, Judith
Marlton, Paula
Gottlieb, David
Munoz, Javier
Seymour, John F.
Roberts, Andrew W.
Wu, Ken
Atwal, Siminder
Novotny, William
Huang, Jane
Tam, Constantine S.
BLOOD, 2019, 134
[49] LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
Woyach, Jennifer A.
Brander, Danielle M.
Hu, Boyu
Rogers, Kerry A.
Omer, Zulfa
Stephens, Deborah M.
Sitlinger, Andrea
Tan, Fenlai
Chen, Yi
Anthony, Stephen P.
Chen, Yu
Shang, Kewei
Byrd, John C.
BLOOD, 2024, 144 : 4623 - 4623
[50] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Brown, J.
Harb, W.
Sharman, J.
Hill, B.
Ma, S.
Miller, T.
Schreeder, M.
Barr, P.
Foran, J.
Gabrilove, J.
Kelly
Burger, Ja
Barnett, E.
Marine, J.
Nava-Parada, P.
Azaryan, A.
Mei, J.
Kipps, T.
HAEMATOLOGICA, 2013, 98 : 217 - 217

← 1 2 3 4 5 →